Just as a follow up from my last post. It is now clear how the government is going to apply the ACA (Affordable Care Act). It will no longer be permitted for insurers to say "we cover Nuvaring, therefore we don't have to cover Annovera because they're both vaginal rings". These two products are not therapeutically equivalent according to the FDA Orange book designation.
The upside of this move is very significant when universally applied. Nexstellis retails for US$224 but MYX achieved price in the first 3 months of FY2024 was US$70, the gap being co-payments paid to patients, free samples to gynaecologists and benefits to pharmacies. With time, this gap will narrow giving Mayne Pharma a 2 to 3 times upside in price. A similar story for Annovera which retails for US$2400. I can't do the sums for this product as I don't have the number of samples sold.
I think the ducks are lining up for this company. Patience is required.
MYX Price at posting:
$5.35 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)